"Institución de referencia en la región y en el país, líder en las prácticas asistenciales que brinda (generando salud y bienestar con sentido humano), referencia local, nacional e internacional en proyectos de investigación biomédica."
Top Sponsors
Top Collaborators
Trials By Phase
Recruitment Status
Top Conditions
Intervention Types
Top Intervention Names
Trials By Gender
Lead Sponsor
# Trials
Boehringer Ingelheim
6
Actelion
4
Gilead Sciences
4
Bayer
3
Pfizer
3
United Therapeutics
3
Reata Pharmaceuticals, Inc.
2
Amgen
1
Eli Lilly and Company
1
Hospital Universitari Vall d'Hebron Research Institute
1
Kowa Research Institute, Inc.
1
Clinical Trials at Instituto de Cardiología de Corrientes
During the past decade, Instituto de Cardiología de Corrientes conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 13 clinical trials were completed, i.e. on
average, 72.2% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 8 clinical trials were completed. i.e. 114.3%
of trials that started reached the finish line.
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
2009-12-01
2014-10-01
Completed
1,156
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Instituto de Cardiología de Corrientes" #1 sponsor was "Boehringer Ingelheim" with 6 trials, followed by "Actelion" with 4 trials
sponsored, "Gilead Sciences" with 4 trials sponsored, "Bayer" with 3 trials sponsored and "Pfizer"
with 3 trials sponsored. Other sponsors include 7 different institutions and
companies that sponsored additional 14 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto de Cardiología de Corrientes"
#1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Canadian VIGOUR Centre" with 1 trials as a collaborator, "Drugs for Neglected Diseases initiative" with 1 trials as a collaborator and "Duke Clinical Research Institute" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 9 trials.
Clinical Trials Conditions at Instituto de Cardiología de Corrientes
According to Clinical.Site data, the most researched conditions in "Instituto de Cardiología de Corrientes" are
"Pulmonary Arterial Hypertension" (8 trials), "Hypertension" (5 trials), "Pulmonary Hypertension" (5 trials), "Atrial Fibrillation" (3 trials) and "Cardiovascular Diseases" (3 trials). Many other conditions were trialed in "Instituto de Cardiología de Corrientes" in a lesser frequency.
Clinical Trials Intervention Types at Instituto de Cardiología de Corrientes
Most popular intervention types in "Instituto de Cardiología de Corrientes" are "Drug" (31 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (15 trials), "Empagliflozin" (3 trials), "Ralinepag" (3 trials), "Darusentan" (2 trials) and "Guanfacine" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Instituto de Cardiología de Corrientes
The vast majority of trials in "Instituto de Cardiología de Corrientes" are
32 trials for "All" genders.
Clinical Trials Status at Instituto de Cardiología de Corrientes
Currently, there are NaN active trials in "Instituto de Cardiología de Corrientes".
undefined are not yet recruiting,
4 are recruiting,
5 are Active, not recruiting,
and 1 are Enrolling by invitation.
In total, there were 15 completed trials in Instituto de Cardiología de Corrientes,
undefined suspended trials,
and 6 terminated clinical trials to date.
Out of the total trials that were conducted in Instituto de Cardiología de Corrientes, 0 "Phase 1"
clinical trials were conducted, 3 "Phase 2" clinical
trials and 28 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".